5VM
5AM Venture Management Portfolio holdings
AUM
$260M
This Quarter Return
-4.79%
1 Year Return
+3.76%
3 Year Return
+144.87%
5 Year Return
+32.61%
10 Year Return
–
AUM
$419M
AUM Growth
+$419M
(-13%)
Cap. Flow
-$12.2M
Cap. Flow
% of AUM
-2.91%
Top 10 Holdings %
Top 10 Hldgs %
66.43%
Holding
32
New
4
Increased
–
Reduced
6
Closed
1
Top Buys
| 1 |
CAMP4 Therapeutics Corporation Common Stock
CAMP
|
$15.3M |
| 2 |
Akero Therapeutics
AKRO
|
$4.59M |
| 3 |
Protara Therapeutics
TARA
|
$4.22M |
| 4 |
Alector
ALEC
|
$1.88M |
Top Sells
| 1 |
Praxis Precision Medicines
PRAX
|
$13.1M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$7.61M |
| 3 |
Cogent Biosciences
COGT
|
$6.07M |
| 4 |
Dianthus Therapeutics
DNTH
|
$4.45M |
| 5 |
Enliven Therapeutics
ELVN
|
$2.75M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Entrada Therapeutics
TRDA
$208M
| $76.2M | 18.19% | 4,408,379 | – | – |
|
|
2
Enliven Therapeutics
ELVN
$1.2B
| $36.7M | 8.75% | 1,629,765 -122,409 | -7% | -$2.75M |
|
3
Skye Bioscience
SKYE
$108M
| $28.1M | 6.69% | 9,913,168 | – | – |
|
|
TECX
4
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $27.5M | 6.57% | 596,660 -49,864 | -8% | -$2.3M |
|
|
ARTV
5
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$76.7M
| $23.7M | 5.66% | 2,353,304 | – | – |
|
|
6
Dianthus Therapeutics
DNTH
$759M
| $22.4M | 5.35% | 1,027,711 -203,908 | -17% | -$4.45M |
|
7
Biohaven
BHVN
$1.63B
| $17.9M | 4.27% | 478,972 | – | – |
|
8
Pharvaris
PHVS
$1.39B
| $15.3M | 3.65% | 797,600 | – | – |
|
9
MoonLake Immunotherapeutics
MLTX
$3.54B
| $15.3M | 3.65% | 282,313 | – | – |
|
|
10
CAMP4 Therapeutics Corporation Common Stock
CAMP
$30.6M
| $15.3M | 3.65% | +2,927,915 | New | +$15.3M |
|
11
Viridian Therapeutics
VRDN
$1.5B
| $14.1M | 3.37% | 736,595 | – | – |
|
|
CNTA
12
Centessa Pharmaceuticals
CNTA
$2.25B
| $13.9M | 3.32% | 830,945 -454,055 | -35% | -$7.61M |
|
13
Erasca
ERAS
$445M
| $13.6M | 3.24% | 5,405,404 | – | – |
|
|
14
Praxis Precision Medicines
PRAX
$958M
| $13.1M | 3.12% | 170,000 -170,000 | -50% | -$13.1M |
|
15
Tyra Biosciences
TYRA
$675M
| $13.1M | 3.12% | 939,298 | – | – |
|
16
Celldex Therapeutics
CLDX
$1.47B
| $12.6M | 3% | 497,270 | – | – |
|
17
EyePoint Pharmaceuticals
EYPT
$797M
| $7.82M | 1.87% | 1,050,000 | – | – |
|
18
Viking Therapeutics
VKTX
$3.04B
| $7.63M | 1.82% | 189,593 -47,967 | -20% | -$1.93M |
|
19
Vor Biopharma
VOR
$250M
| $7.06M | 1.69% | 6,361,723 | – | – |
|
20
AnaptysBio
ANAB
$569M
| $4.74M | 1.13% | 357,733 | – | – |
|
|
21
Akero Therapeutics
AKRO
$3.74B
| $4.59M | 1.1% | +165,000 | New | +$4.59M |
|
22
scPharmaceuticals
SCPH
$295M
| $4.25M | 1.01% | 1,200,647 | – | – |
|
|
23
Protara Therapeutics
TARA
$120M
| $4.22M | 1.01% | +800,000 | New | +$4.22M |
|
24
GH Research
GHRS
$837M
| $4.01M | 0.96% | 572,665 | – | – |
|
25
Rallybio
RLYB
$22.4M
| $3.49M | 0.83% | 3,630,724 | – | – |
|